Intelligent Abuse-Deterrent Pharmaceutical Systems
Legal Citation
Summary of the Inventive Concept
The inventive concept integrates Acurx Pharmaceuticals' patented abuse-deterrent technology with cutting-edge technologies like AI, IoT, blockchain, and nanomaterials to create a new generation of smart pharmaceutical systems that optimize drug release, minimize abuse potential, and enhance patient safety.
Background and Problem Solved
The original patent addressed the need for abuse-deterrent pharmaceutical compositions. However, the growing opioid crisis and increasing concerns about prescription drug abuse necessitate more sophisticated solutions. The new inventive concept builds upon the original patent's foundation to create a more comprehensive and adaptive system that addresses the complex challenges of drug abuse and misuse.
Detailed Description of the Inventive Concept
The inventive concept combines Acurx Pharmaceuticals' pH-modifying technology with machine learning-based dosage monitoring, blockchain-based secure data storage, IoT-enabled ingestion tracking, and nanomaterial-based sensors. These integrated components enable real-time monitoring, adaptive drug delivery, and optimized release rates in response to patient behavior, dosage history, and environmental factors. The system's synergistic combination of technologies ensures a more effective and personalized approach to drug delivery, minimizing the potential for abuse and maximizing therapeutic efficacy.
Novelty and Inventive Step
The new claims introduce a paradigm shift in pharmaceutical systems by integrating distinct technologies to create a holistic, adaptive, and intelligent system that surpasses the original patent's limitations. The inventive concept's novelty lies in its ability to predict and respond to patient behavior, environmental factors, and dosage history in real-time, thereby providing a more effective and safer approach to drug delivery.
Alternative Embodiments and Variations
Alternative embodiments may include variations in the type of machine learning algorithm used, the specific IoT-enabled devices employed, or the nanomaterials utilized. Additionally, the inventive concept could be adapted for use with different pharmaceutical compositions, dosage forms, or routes of administration.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of pain management, addiction treatment, and personalized medicine. The system's ability to minimize abuse potential, optimize drug release, and enhance patient safety makes it an attractive solution for healthcare providers, pharmaceutical companies, and patients alike.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/02 |
| A | A61 | A61K9/2009 |
| A | A61 | A61K9/2027 |
| A | A61 | A61K9/2077 |
| A | A61 | A61K31/5517 |
| A | A61 | A61K47/32 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulations with abuse-deterrent technologies, focusing on controlled drug release mechanisms, pharmaceutical composition design, and drug delivery system optimization
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist or chemical engineer with advanced degree, expertise in drug formulation, knowledge of controlled release technologies, understanding of polymer chemistry, and familiarity with abuse-deterrent pharmaceutical design strategies
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring technologies with existing abuse-deterrent pharmaceutical compositions represents a predictable extension of known drug delivery strategies. The source patent's foundational work on pH-modulated drug release provides a clear technical framework for incorporating advanced monitoring and adaptive release technologies. The proposed variations represent logical combinations of known techniques in pharmaceutical engineering and digital health monitoring.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,629 |
|---|---|
| Title | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
| Assignee(s) | Acurx Pharmaceuticals, Inc. |